Transcutaneous port for continuous duodenal levodopa/carbidopa administration in Parkinson's disease

Movement Disorders

Volumn 26, Issue 2, 2011, Pages 331-334

  Meppelink, Anne Marthe ^a   Nyman, Rickard ^b   van Laar, Teus ^a   Drent, Martje ^a   Prins, Ted ^a   Leenders, Klaus Leonhard ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Duodopa; Parkinson's disease; T port

Indexed keywords

CARBIDOPA PLUS LEVODOPA; TITANIUM;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTINUOUS INFUSION; DRUG DELIVERY SYSTEM; DUODENUM; EXPLANT; FEMALE; FOLLOW UP; GASTROJEJUNOSTOMY; HUMAN; IMPLANTATION; INSTILLATION SITE IRRITATION; MALE; MEDICAL APPARATUS, EQUIPMENT AND SUPPLIES; MOTOR PERFORMANCE; PARKINSON DISEASE; POLYNEUROPATHY; PRIORITY JOURNAL; QUALITY OF LIFE; TRANSCUTANEOUS TITANIUM PORT;

ADMINISTRATION, CUTANEOUS; ADULT; AGED; ANTIPARKINSON AGENTS; CARBIDOPA; DRUG COMBINATIONS; DUODENUM; FEMALE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE; PATIENT SATISFACTION; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 79952676377     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.23408     Document Type: Article

References (12)

1. Marsden CD. Problems with long-term levodopa therapy for Parkinson's disease. Clin Neuropharmacol 1994; 17 Suppl 2: S32-S44.
2. Bredberg E, Nilsson D, Johansson K, et al. Intraduodenal infusion of a water-based levodopa dispersion for optimisation of the therapeutic effect in severe Parkinson's disease. Eur J Clin Pharmacol 1993; 45: 117-122.
3. Nilsson D, Nyholm D, Aquilonius SM. Duodenal levodopa infusion in Parkinson's disease--long-term experience. Acta Neurol Scand 2001; 104: 343-348.
4. Nyholm D, Lewander T, Johansson A, et al. Enteral levodopa/carbidopa infusion in advanced Parkinson disease: long-term exposure. Clin Neuropharmacol 2008; 31: 63-73.
5. Odin P, Wolters E, Antonini A. Continuous dopaminergic stimulation achieved by duodenal levodopa infusion. Neurol Sci 2008; 29 Suppl 5: S387-S388.
6. Devos D. Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson's disease. Mov Disord 2009; 24: 993-1000.
7. Nyman R, Lundgren D, Nyholm D. Soft tissue-anchored transcutaneous port attached to an intestinal tube for long-term gastroduodenal infusion of levodopa/carbidopa in Parkinson disease. J Vasc Interv Radiol 2009; 20: 500-505.
8. Nyman R, Eklof H, Eriksson LG, et al. Soft-tissue-anchored transcutaneous port for long-term percutaneous transhepatic biliary drainage. Cardiovasc Intervent Radiol 2005; 28: 53-59.
9. Peto V, Jenkinson C, Fitzpatrick R. PDQ-39: a review of the development, validation and application of a Parkinson's disease quality of life questionnaire and its associated measures. J Neurol 1998; 245 Suppl 1: S10-S14.
10. Toth C, Brown MS, Furtado S, Suchowersky O, Zochodne D. Neuropathy as a potential complication of levodopa use in Parkinson's disease. Mov Disord 2008; 23: 1850-1859.
11. Honig H, Antonini A, Martinez-Martin P, et al. Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life. Mov Disord 2009; 24: 1468-1474.
12. Raudino F, Garavaglia P, Pianezzola C, et al. Long-term experience with continuous duodenal levodopa-carbidopa infusion (Duodopa): report of six patients. Neurol Sci 2009; 30: 85-86.